Share

Artificial Pancreas Can Prevent Dangerously Low Blood Sugar in People with Type 1 Diabetes

New system reduces the risk of exercise-related hypoglycemia A new artificial pancreas system can prevent hypoglycemia—episodes of dangerously low blood sugar—during and after heavy exercise in people with type 1 diabetes, according to a small study published in The Journal of Clinical Endocrinology & Metabolism. Despite advances in treatment, blood sugar control in type 1 diabetes remains challenging. The artificial pancreas has the potential to...
Share

Lilly Launches Initiative “Know Before the Low” to Help Patients with Diabetes Recognize and Share Symptoms

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies Eli Lilly and Company launched a new initiative earlier this summer to raise awareness about being prepared for these unpredictable conditions. With Know Before the...
Share

Next-Generation Integrated Continuous Glucose Monitor Now Available Following FDA Clearance

An integrated continuous glucose monitor (iCGM) is now available for adults and now children (4+ years) living with diabetes, following its clearance in June from the U.S. Food and Drug Administration (FDA). Abbot is marketing this new technology as the FreeStyle® Libre 2. The FreeStyle Libre 2 system uses Bluetooth to automatically alerts users when...
Share

Virtual Endocrinology: The Rise of Telemedicine During COVID-19

july cover How clinicians treat patients has been drastically reimagined during the COVID-19 pandemic due to social distancing requirements. Since patients still need to see their doctors one way or another, telemedicine has filled the gap and has been embraced by both the healthcare community and patients alike. Chirag R. Kapadia, MD, is an endocrinologist at Phoenix...
Share

FDA Approves Leuprolide Acetate for Injectable Suspension for Pediatric Patients with Central Precocious Puberty

The U.S. Food and Drug Administration (FDA) last month approved leuprolide acetate for injectable suspension for the treatment of pediatric patients two years of age and older with central precocious puberty (CPP). Tolmar Pharmaceuticals is marketing the drug as Fensolvi. Leuprolide acetate is the most widely used treatment for CPP. Fensolvi utilizes a proprietary polymeric gel...

The endocrine system is a miracle of evolution — a highly complex machine that carries out multiple functions within the body with precision and efficiency. It’s no wonder that as our understanding of the endocrine system advances, the technology we use to study and care for it also becomes more advanced as it approaches the endocrine system in terms of sophistication. Whether that endocrinology technology takes the form of new, advanced medicines, sophisticated imaging and diagnostic technology, or innovative therapies that make life easier for patients, endocrine science continues to push the boundaries and enter new territory. For endocrinologists, staying informed about all of the latest advances in technology and effective treatment options mean better overall care for their patients.

This section compiles the latest news regarding technological advances in endocrinology, featuring articles written for and by the leading voices in endocrine science today. Here, you’ll find articles relating to all the most recent happenings in technology, techniques and general information of interest to endocrinologists. Keeping up with the latest advancements in the field will help you know where medicine has been, where it will advance next, and how it will look in the future. Endocrine News brings you everything you need to know about the future of endocrinology so you’ll know exactly when science catches up to your patients’ needs. The field of endocrinology continues to advance, and Endocrine News is your source for advancing your own knowledge of everything that’s going on for today and tomorrow.